Prelude Therapeutics Incorporated announced multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude's CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for SMARCA2 degrader compound, PRT3789.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 USD | +0.29% |
|
-7.24% | -18.97% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.97% | 190M | |
+16.71% | 44.63B | |
+42.66% | 40.46B | |
-7.92% | 38.07B | |
+33.09% | 32.27B | |
-7.10% | 27.3B | |
+14.46% | 26.53B | |
+46.73% | 14.06B | |
+34.07% | 12.54B | |
-7.61% | 11.28B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference